88th Report in 2010: History of STI in Bio-Pharmaceutical Industry in China and Recommendations on Its Development

March 24,2011

|

xiaoluo

 

Abstract: Development of bio-pharmaceutical industry in China generally underwent the stages of starting, emerging, and rapid development in the past several decades. In comparison with large international enterprises in the pharmaceutical industry, the enterprises in China now face issues like acute shortage in R&D input, lacking of core technologies, and less developed innovative system for their later entry into the industry. The article proposes several recommendations for expediting the improvement of technological competitiveness, including establishing a mechanism gradually for “pressing” innovation with market forces, lowering market entry conditions for technology result with comparable advantages, cultivating and developing advantageous core enterprises, and expediting building of standards system and foundation of statistics.